This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Bipolar Disorder: A Critical Appraisal of Diagnosis and Treatment

Bipolar Disorder: A Critical Appraisal of Diagnosis and Treatment


Slide Lecture Series

Time to Complete

1 hour


March 15, 2019


March 14, 2020
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 credit(s)TM
1.00 / AANP Contact Hour (includes 0.25 pharmacology credit)
1.00 / AAPA Category 1 CME credits

Accredited Provider

This continuing education activity is provided by Vindico Medical Education.

Commercial Supporter

This activity is supported by educational grants from Otsuka America Pharmaceutical, Inc. and Lundbeck; and Sunovion Pharmaceuticals Inc.

Program Description

Bipolar disorder comprises a spectrum of diseases, characterized by recurrent periods of mania, hypomania, or episodes of mixed features, with a prevalence of approximately 3% of the US population. Many patients with bipolar disorder are not adequately treated and often receive delayed or incorrect diagnoses due to overlapping symptoms with other psychiatric illnesses. In this continuing education activity, experts in the field will discuss how to differentiate bipolar disorder from other psychiatric illnesses and ways to improve adherence to bipolar treatments, as well as review current and emerging pharmacotherapies.

Intended Audience

The intended audience for this activity is psychiatrists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with bipolar disorder.

Purpose/Educational Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Incorporate novel approaches that differentiate bipolar disorder from other psychiatric conditions in adults and adolescents.
  • Apply evidence-based medicine on efficacy and safety, as well as on patient characteristics, when selecting treatment for specific phases of bipolar disorder.
  • Utilize strategies that facilitate medication adherence in patients with bipolar disorder.

Conflict Of Interest Disclosure Policy

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.


Activity Chair:
Leslie Citrome, MD, MPH

Clinical Professor of Psychiatry & Behavioral Sciences
New York Medical College
Valhalla, NY

Dr. Citrome discloses the following:
Royalty: UpToDate, Wiley
Consulting Fee: Acadia, Alkermes, Allergan, Indivior, Intra-Cellular Therapeutics, Janssen, Lundbeck, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva, Vanda
Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva
Ownership Interest: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer

Joseph F. Goldberg, MD
Clinical Professor of Psychiatry
The Icahn School of Medicine at Mount Sinai
Director, Affective Disorders Research Program
Silver Hill Hospital
New York, NY

Dr. Goldberg discloses the following:
Royalty: American Psychiatric Publishing, Inc.
Consulting Fee: Neurocrine, Otsuka, Sunovion, WebMD
Speakers Bureau: Allergan, Neurocrine, Otsuka, Sunovion, Takeda-Lundbeck

Terence A. Ketter, MD
Professor Emeritus of Psychiatry & Behavioral Sciences
Stanford University
Stanford, CA

Dr. Ketter discloses the following:
Royalty: American Psychiatric Publishing, Inc.
Consulting Fee: Alkermes, Xcenda/Neurocrine Biosciences
Speakers Bureau: Otsuka
Contracted Research: Merck, Sunovion
Ownership Interest (spouse): Janssen

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
has no relevant financial relationships to disclose.
Linda A. Giarraputo, PA-C has no relevant financial relationships to disclose.

Accredited Provider Disclosure

Vindico staff has no relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

Vindico Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.




AAPA Category I CME credit

Accreditation Statement

This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

Designation Statement

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid for one year from 03/15/2019. PAs should only claim credit commensurate with the extent of their participation.

Successful completion of the post-test is required to earn AAPA Category 1 CME credit. Successful completion is defined as a cumulative score of at least 75 percent correct.




CE for Nurse Practitioners

Accreditation Statement

This activity was planned in accordance with AANP CE Standards and Policies.

Designation Statement

This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19023587.

This enduring material is approved for 1 year from the date of original release, March 15, 2019 to March 14, 2020.

Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


To participate in this CE activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 6 of the 8 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, myCME will issue a CE certificate.

If you have CME Questions, please contact Vindico at

Privacy Policy


Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue